What we do
HQ & Pipeline
Digital Therapeutics
Discover our story
Key News
FEBRUARY 3, 2023
NDA submitted with the FDA for OX124 a highdose medication for opioid overdose
JANUARY 26, 2023
Orexo Interim Report Q4 2022, incl. Full Year Report
JANUARY 25, 2023
New blog post - "Charlie’s overdose: why we need to tell young people about fake pills"
Listed on Nasdaq Stockholm´s mainlist
Orexo is listed on Nasdaq Stockholm´s main list and can also be traded in the US at the OTCQX Market.
MODIA® - our digital therapy for opioid use disorder
- to be used along with pharmaceuticals
- 180 days treatment
- grounded in cognitive behavioral therapy techniques
- available 24/7
- ongoing clinical trial incl. more than 430 patients
News Flow
Press Releases & News
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose
Invitation to presentation of Orexo´s Interim Report Q4 2022 incl. Full Year Report
Orexo initiates exploratory feasibility studies of amorphOX[®] with two leading biopharmaceutical and vaccine companies
Edward Kim, M.D., Chief Medical Officer: “I joined Orexo to make a difference in the lives of people suffering from opioid use disorder”
Orexo Social
@OrexoABpubl
3 February 2023
Life Science Sweden om att vi lämnat in en FDA-ansökan om att få OX124 - vårt överdosläkemedel - godkänt i USA.… https://t.co/pAjhD063kD
@OrexoABpubl
3 February 2023
#Orexo has filed a New Drug Application to the FDA for OX124, our life-saving medication that reverses the effects… https://t.co/WbspScyY7k
@OrexoABpubl
31 January 2023
Klas Palin, hälsovårdsanalytiker på Erik Penser Bank, i en lång intervju med VD Nikolaj Sørensen. På agendan: Opera… https://t.co/8nhwCYB7hL
Financial Snapshot
Group net revenues
624.3 MSEK
LTM1
Group EBITDA
-115.2 MSEK
LTM1
US Pharma segment EBIT
308.4 MSEK
LTM1
Cash position
359.1 MSEK
Q4 2022
1 Last Twelve Months, Q122-Q422, for more information about financial development Link